1Andre T, Boni C, Mounedji - Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J]. N Engl J Med,2004,350(23) :2 343. 被引量：1
2Wolmark N,Rockette H, Mamounas E,et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin,fluorouracil and levamisole, and fluorouracil, leucovorin,and levamisole in patients Dukes B and C carcinoma of the colon:result from National Surgical Adjuvant Breast and Bowel Project[J]. J Glin Oncol, 1999,17 (11 ) :3 553 - 3 559. 被引量：1
3Andre T,Colin P,Louvet C,et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage Ⅱ and Ⅲ colon cancer:Results of a randomized trial [J]. J Clin Oncol,2003,21 ( 15 ) :2 896. 被引量：1
5Cassidy J, Scheithauer W, McKendrick J, et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study) : Efficacy results of a phase Ⅲ trial [J]. Proc Am Soc Clin Oncol, 2004,22:3 509. 被引量：1
6Cutsem EV, Hof PM, Harper P, et al. Oral capeeitabine vs intravenous 5-fluorouracil and leucovorin:integrated efficacy data and novel analyses from two large, randomized, phase Ⅲ trials[J]. Br J Cancer, 2004, 90(6) : 1 190 - 1 197. 被引量：1
7Cassidy J,Tabernero J,Twelves C,et al. XELOX(capecitabine plus oxaliplatin) :active first- line therapy for patients with metastatic colorectal cancer [ J ]. J Clin Oncol, 2004,22 ( 11 ) : 2 084 - 2 091. 被引量：1
8Ahn J, Jung KH,Park YS, et al. Phase Ⅱ trial of irinoteean and capeeitabine in patients with advanced coloreetal cancer (ACRC)(Abstr)[J]. J Clin Oncol,2005,23(16) :3 714. 被引量：1
9Douillard JY, Cunningham D, Roch AD, et al. Irinotecan combined with fluorouracil as first line treatment for metastatic colorectal cancer multicentre randomized trim[J]. Cancer,2000,355:1 041 - 1 047. 被引量：1
10Sahz LD, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, lrinoteean study group[J]. N EngL J Med,2000,343:905 - 914. 被引量：1
2Giantonio BJ,Catalano PJ,Meropol NJ,et al.High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer:Results from the Eastern Cooperative Oncology Group (ECOG) study E3200[ J].Pro Am Soc Clin Oncol,2005,23:1s Abstr 2. 被引量：1
3Sandler AB,Gray R,Brahmer J,et al.Randomized phase Ⅱ/Ⅲ trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC):An Eastern Cooperative Oncology Group (ECOG) trial-E4599 [ J].Pro Am Soc Clin Oncol,2005,23:2s LBA4. 被引量：1
4Half E,Broaddus R,Danenberg KD,et al.HER-2 receptor expression,localization,and activation in colorectal cancer cell lines and human tumors [ J ].Int J Cancer,2004,108:540-548. 被引量：1
5Sekharam M,Zhao H,Sun M,et al.Insulin-like growth factor 1receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway[J].Cancer Res,2003,63:7708-7716. 被引量：1
6Chun YJ,Park S,Yang SA,et al.Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells[ J].Toxicol Lett,2003,146:75-81. 被引量：1
7Ohana G,Bar-Yehuda S,Arich A,et al.Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101 [ J].Br J Cancer,2003,89:1552-1558. 被引量：1
8Hainsworth JD,Sosman JA,Spigel DR,et al.Phase Ⅱ trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma(RCC) [ J].Proc Am Soc Clin Onco1,2004,22:382s(abstr 4502). 被引量：1
9Motzer RJ,Rini BI,Michaelson MD,et al.SU0 11248,a novel tyrosine kinase inhibitor,shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma:results of a phase 2 trial[J].Proc Am Soc Clin 0ncol,2004,22:382s (abstr 4500). 被引量：1
10Drach J,Kaufmann H,Woehrer S,et al.Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma[ J].Proc Am Soc Clin Oncol,2004,22:578s (abstr 6583). 被引量：1
